TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: NCCN Guidelines also recommend brentuximab vedotin as the preferred choice of second-line therapy for relapsed/refractory ALCL and other CD30-positive entities, including PTCL-NOS [80].